Literature DB >> 8514462

Altered serotonergic activity in women with dysphoric premenstrual syndromes.

U Halbreich1, H Tworek.   

Abstract

OBJECTIVE: Dysphoric Premenstrual Syndromes (PMS) are quite prevalent and in some women they are severe enough to warrant treatment. Their pathophysiology is still unknown, despite increased interest and research. Here we review the possible role of serotonin in the multidimensional interactive pathophysiology of PMS.
METHOD: Over 170 articles are reviewed. An extensive library search has been conducted and articles are included because of their relevance to: 1) the phenomenology of PMS; 2) the putative association of serotonergic (5-HT) activity with syndromes that occur premenstrually; 3) changes in 5-HT activity along the menstrual cycle, especially the late luteal phase; 4) influence of gonadal hormones on serotonergic functions; 5) endocrine strategies for assessment of 5-HT abnormalities; and 6) treatment studies of PMS with serotonergic agonists. RESULTS AND
CONCLUSIONS: The data presented here suggest that post-synaptic serotonergic responsivity might be altered during the late-luteal-premenstrual phase of the menstrual cycle. Some serotonergic functions of women with PMS might be altered during the entire cycle and be associated with a vulnerability trait. It is hypothesized that gonadal hormones might cause changes in levels of activity of 5-HT systems as part of a multidimensional interactive system. Strategies to evaluate 5-HT activities in the context of the menstrual cycle are discussed--leading to the conclusion that the most promising approach is active stimulation with specific post-synaptic serotonin agonists. Treatment outcome studies of some imperfect compounds that are currently applied as a symptomatic treatment of PMS support the notion that 5-HT is involved in the pathophysiology of these syndromes.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8514462     DOI: 10.2190/J2W0-RTGD-NYKK-FF77

Source DB:  PubMed          Journal:  Int J Psychiatry Med        ISSN: 0091-2174            Impact factor:   1.210


  14 in total

1.  Pilot study of the efficacy and safety of a modified-release magnesium 250 mg tablet (Sincromag) for the treatment of premenstrual syndrome.

Authors:  S Quaranta; M A Buscaglia; M G Meroni; E Colombo; S Cella
Journal:  Clin Drug Investig       Date:  2007       Impact factor: 2.859

2.  Smaller brain size likely in young adults (<40 years old) with depressive symptoms compared to healthy controls: a retrospective study.

Authors:  Michito Adachi; Akiko Shibata; Takamichi Sato; Etsuko Kawaguchi
Journal:  Jpn J Radiol       Date:  2011-01-26       Impact factor: 2.374

Review 3.  The 5-HT1A receptor in Major Depressive Disorder.

Authors:  Joshua Kaufman; Christine DeLorenzo; Sunia Choudhury; Ramin V Parsey
Journal:  Eur Neuropsychopharmacol       Date:  2016-01-11       Impact factor: 4.600

4.  Ovarian steroid action on tryptophan hydroxylase protein and serotonin compared to localization of ovarian steroid receptors in midbrain of guinea pigs.

Authors:  N Z Lu; T A Shlaes; C Gundlah; S E Dziennis; R E Lyle; C L Bethea
Journal:  Endocrine       Date:  1999-12       Impact factor: 3.633

5.  High fat diet decreases beneficial effects of estrogen on serotonin-related gene expression in marmosets.

Authors:  Cynthia L Bethea; Arubala P Reddy; Matthew Flowers; Robert A Shapiro; Ricki J Colman; David H Abbott; Jon E Levine
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2014-12-24       Impact factor: 5.067

Review 6.  Role of estrogen in the aetiology and treatment of mood disorders.

Authors:  U Halbreich; L S Kahn
Journal:  CNS Drugs       Date:  2001       Impact factor: 5.749

Review 7.  Insulin sensitivity and premenstrual syndrome.

Authors:  Kimberly K Trout; Karen L Teff
Journal:  Curr Diab Rep       Date:  2004-08       Impact factor: 4.810

Review 8.  Update on research and treatment of premenstrual dysphoric disorder.

Authors:  Joanne Cunningham; Kimberly Ann Yonkers; Shaughn O'Brien; Elias Eriksson
Journal:  Harv Rev Psychiatry       Date:  2009       Impact factor: 3.732

9.  Timing of alcohol use and the incidence of premenstrual syndrome and probable premenstrual dysphoric disorder.

Authors:  Elizabeth R Bertone-Johnson; Susan E Hankinson; Susan R Johnson; JoAnn E Manson
Journal:  J Womens Health (Larchmt)       Date:  2009-12       Impact factor: 2.681

Review 10.  Selective serotonin reuptake inhibitors for premenstrual dysphoric disorder: the emerging gold standard?

Authors:  Teri Pearlstein
Journal:  Drugs       Date:  2002       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.